+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cluster Of Differentiation 3"

Blood Cancer Drugs Market Report 2025 - Product Thumbnail Image

Blood Cancer Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Bi-Specific MAbS Market Report 2025 - Product Thumbnail Image

Bi-Specific MAbS Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2025 - Product Thumbnail Image

Immuno-Oncology Drugs Market Report 2025

  • Report
  • March 2025
  • 250 Pages
  • Global
From
Tumor Infiltrating Lymphocytes Market Report 2025 - Product Thumbnail Image

Tumor Infiltrating Lymphocytes Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Thumbnail Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 450 Pages
  • Global
From
Anti-CD38 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD38 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 60 Pages
  • Global
From
TCR Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

TCR Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 280 Pages
  • Global
From
Bispecific Antibodies for Cancer Market 2025-2029 - Product Thumbnail Image

Bispecific Antibodies for Cancer Market 2025-2029

  • Report
  • February 2025
  • 233 Pages
  • Global
From
Bispecific Antibody & Cancer Patent Landscape Analysis - Product Thumbnail Image

Bispecific Antibody & Cancer Patent Landscape Analysis

  • Report
  • January 2025
  • 120 Pages
  • Global
Protein Kinase C Theta Type - Pipeline Review, H2 2020 - Product Thumbnail Image

Protein Kinase C Theta Type - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 33 Pages
  • Global
From
NK Cell therapies - Pipeline Insight, 2024 - Product Thumbnail Image

NK Cell therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
CAR T-cell Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Gastric Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 550 Pages
  • Global
From
Advanced Merkel cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Merkel cell carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Anti-CD20 antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD20 antibody - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Cluster of Differentiation 3 (CD3) market is a subset of the oncology drug market that focuses on drugs that target the CD3 molecule. CD3 is a protein found on the surface of T-cells, which are a type of white blood cell that plays a key role in the body's immune system. CD3-targeting drugs are used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. These drugs work by blocking the CD3 molecule, which prevents the T-cells from attacking healthy cells and helps to reduce the growth of cancer cells. Some of the companies in the CD3 market include Novartis, Merck, Pfizer, and Bristol-Myers Squibb. These companies have developed a range of CD3-targeting drugs, including Imbruvica, Keytruda, and Opdivo. These drugs have been approved by the FDA for the treatment of various types of cancer and are widely used in the oncology field. Show Less Read more